Introduction
============

The results of meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) showed that postmastectomy radiotherapy (PMRT) reduced the risks of recurrence and cancer death \[[@b1-crt-2015-172]\]. Updated studies confirmed benefits of PMRT in patients with N1 disease, irrespective of the use of systemic therapy and axillary dissection \[[@b2-crt-2015-172],[@b3-crt-2015-172]\]. When using modern treatment approaches, accurate identification of high-risk patients for PMRT while sparing the remaining patients from potentially unnecessary and costly therapy, and continuing to provide them with excellent local control rates is imperative \[[@b4-crt-2015-172],[@b5-crt-2015-172]\]. However, the indications for PMRT are still determined on a case-by-case basis, and definitive indications have varied significantly across institutions and changed over time. Thus, the development of a practical prognostic indicator for recurrence is required to optimize the application of PMRT for this controversial situation.

^18^F-Fluorodeoxyglucose/positron emission tomography (^18^F-FDG/PET), which detects the enhanced glycolysis of tumors, has emerged as a useful imaging tool in staging, evaluation of treatment response, and predicting the prognosis of breast cancer \[[@b6-crt-2015-172]\]. In Korea, ^18^F-FDG/PET staging is reimbursed for patients who are newly diagnosed with breast cancer; as a result, its use has increased for both locally advanced and early-stage breast cancers. Here, we sought to evaluate the potential utility of ^18^F-FDG/PET for predicting prognosis in a group of T1-T2/N1 breast cancer patients who underwent mastectomy, and we assessed the question of whether this PET-based high-risk group was at increased risk of locoregional recurrence after treatment without PMRT, who might be potential candidates for adjuvant radiation therapy.

Materials and Methods
=====================

1. Patients
-----------

A total of 712 consecutive patients who underwent mastectomy and were diagnosed with pathologic T1-T2/N1 breast cancer at a single institution between 2003 and 2012 were identified. Of these 712 patients, the 109 who underwent preoperative ^18^F-FDG/PET scanning were included in the current study. At our institution, ^18^F-FDG/PET staging was first offered to patients with early breast cancer in November 2003. An increase in systemic staging with ^18^F-FDG/PET was observed in our study cohort during the study period (2003-2009: n=46/361, 14% vs. 2010-2012: n=63/114, 55%).

2. Treatment
------------

All patients underwent modified radical mastectomy. Sentinel lymph node (SLN) sampling was performed in all patients, except those (19%) who had biopsy-confirmed or suspicious axillary nodal metastasis on PET imaging. If the frozen section of the SLN was positive, the patient underwent completion of axillary dissection (median, 12 nodes; range, 4 to 34 nodes). Although PMRT was delivered at the physician's discretion, it was generally performed for patients with high-risk features (mainly based on the number of positive lymph nodes). Adjuvant systemic therapy was selected after discussion with the patient's medical oncologist.

3. ^18^F-FDG/PET
----------------

^18^F-FDG/PET scans were performed using a dedicated PET/computed tomography (CT) scanner (Discovery STE, GE Healthcare, Little Chalfont, UK, or Biograph TruePoint 40, Siemens Healthcare, Erlangen, Germany). The mean time interval from PET scan to mastectomy was 10±9 days. The detailed protocols for measurement of blood glucose concentration, determination of injected ^18^F-FDG quantity, low-dose and contrast enhanced CT and PET scans, and PET data reconstruction have all been described previously \[[@b7-crt-2015-172]\]. Semiquantitative and volumetric measurements of maximum standardized uptake value (SUV~max~), mean SUV (SUV~mean~), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of whole body tumors were performed with the PETedge tool that is available in MIMvista software (MIMvista Corp., Cleveland, OH), according to the protocol of Liao et al. \[[@b8-crt-2015-172]\]. After contouring the tumor using the PETedge tool, volumes of interest (VOIs) were automatically produced by spatial derivatives to locate the tumor surface. The estimated VOIs were manually adjusted using a 2-D "ball" contouring tool. In this study, SUV~max~ was the maximum SUV~max~ of all tumors either in breast tissue or in the axillary area. TLG was calculated as follows: TLG=SUV~mean~×MTV. MTV and TLG were computed after summing the corresponding values of all tumors. ^18^F-FDG/PET was administered at the clinical discretion of the treating physician during the study period.

4. Statistical analysis
-----------------------

The primary end-point of our study was relapse-free survival (RFS), defined as the length of time from the date of mastectomy to any type of relapse. RFS was estimated using the Kaplan-Meier method. Comparisons of PET parameters according to clinical parameters or any recurrence (locoregional recurrence and distant metastasis as first site of failure) were performed using t tests. One-way analysis of variance (ANOVA) with a *post-hoc* Bonferroni's correction was used for multiple comparisons. Receiver operating characteristics (ROC) analyses were performed to determine which parameter was most useful for predicting disease recurrence risk. Univariate and multivariate analyses of disease-free survival (DFS) were performed using Cox's proportional hazards regression method to assess whether the PET parameter retained statistical significance after adjusting for known clinicopathologic variables. Clinically relevant variables were selected, and multivariate analysis was performed using backwards elimination. The method of Contal and O'Quigley was used to determine the cut-off point for the PET parameter, to allow objective dichotomization \[[@b9-crt-2015-172]\]. Using this method, the optimal cut-off point is determined by setting it to the point that maximizes the model likelihood. Because all possible cut-off points are assessed, an adjustment is applied to the p-value to control for type I error. Next, to identify the subgroup of patients who may benefit from PMRT, a secondary analysis was performed, excluding patients who underwent PMRT (no-PMRT cohort). The level of statistical significance was set at 0.05. All statistical analyses were performed using SPSS ver. 20.0 (IBM SPSS Statistics, IBM Co., Armonk, NY) or SAS (SAS Institute Inc., Cary, NC).

Results
=======

1. Patient, tumor, and treatment characteristics
------------------------------------------------

The median follow-up period was 46.7 months (range, 14 to 127 months). Data on patient, tumor, and treatment characteristics are summarized in [Table 1](#t1-crt-2015-172){ref-type="table"}. The median age of patients was 49 years (range, 27 to 92 years). The mean tumor size was 2.0±0.9 cm (range, 0.4 to 4.5 cm). SLN sampling was performed in 87 patients (81%), with a median of 3 (range, 1 to 7) identified. Axillary dissections were performed in all patients with a median of 12 (range, 4 to 34) total nodes dissected. Adjuvant systemic therapy was administered in most patients (105 of 109, 96%) as follows: chemotherapy (n=94, 86%) and endocrine therapy (n=58, 54%). PMRT was delivered to 34% of the patients.

2. Semiquantitative analysis of PET parameters
----------------------------------------------

Most patients (97.2%) had ^18^F-FDG--avid tumors in the primary site, and 22 patients (20.2%) had ^18^F-FDG--avid tumors in axillary nodes. For whole body tumors (WT), the average SUV~max~, MTV, and TLG was 4.79±3.07, 7.07±5.97 mL, and 20.22±26.0, respectively. For ^18^F-FDG--avid tumors in breast tissue (n=106), the average SUV~max~, MTV, and TLG was 4.75±3.01, 5.92±5.02 mL, and 17.49±23.48, respectively. For ^18^F-FDG--avid tumors in axillary nodes (n=22), the average SUV~max~, MTV, and TLG was 4.70±3.38, 4.09±4.14 mL, and 12.00±16.13, respectively.

Significant correlations were observed among three parameters (TLG~WT~ vs. MTV~WT~, Spearman's rho=0.882; TLG~WT~ vs. SUV~max~ ~WT~, rho=0.718; MTV~WT~ vs. SUV~max~ ~WT~, rho=0.574; all p \< 0.001). Differences in SUV~max~ ~WT~, MTV~WT~, and TLG~WT~ according to clinicopathologic parameters are shown in [Table 2](#t2-crt-2015-172){ref-type="table"}. A significantly higher mean SUV~max~ ~WT~ was observed for invasive ductal carcinoma (IDC) tumors compared with non-IDC tumors (p \< 0.001). Significantly higher mean values of SUV~max~ ~WT~, MTV~WT~, and TLG~WT~were observed in T2, high-grade (G3), estrogen receptor (ER)--negative, or progesterone receptor (PR)--negative, tumors than in T1, non-high grade (G1/2), ER+, or PR+ tumors, respectively (all p \< 0.05). In addition, as T stage increased, SUV~max~ of breast, axillary nodes, and WT were increased and more FDG-avid tumors were found in axillary nodes (T1a, 0%; T1b, 13.3%; T1c, 20.5%; T2, 22.9%) ([Table 3](#t3-crt-2015-172){ref-type="table"}).

3. Recurrence
-------------

At the time of analysis, six patients (6%) had experienced any recurrences, three presented with locoregional recurrence and three presented with distant metastasis. Six patients (6%) died, either with (n=2) or without (n=4) disease progression. The 3-year RFS and overall survival (OS) rates were 95.2% (95% confidence interval \[CI\], 91.1% to 99.3%) and 91.8% (95% CI, 84.7% to 98.9%), respectively. The relationship between SUV results and tumor recurrence was examined; patients with any recurrence had higher levels of SUV~max~ ~WT~, MTV~WT~, and TLG~WT~ at baseline than those without any recurrence ([Fig. 1A](#f1-crt-2015-172){ref-type="fig"}). Similar levels of SUV~max~ ~WT~, MTV~WT~, and TLG~WT~ were observed between patients who failed locoregionally or distally (all p=0.001; ANOVA with Bonferroni correction) ([Fig. 1B](#f1-crt-2015-172){ref-type="fig"}).

4. Usefulness of PET for predicting recurrence
----------------------------------------------

ROC curves were generated for SUV~max~ ~WT~, MTV~WT~, and TLG~WT~ ([Fig. 2](#f2-crt-2015-172){ref-type="fig"}). In the ROC analyses, the areas under the curves (AUCs) were 0.824 (95% CI, 0.715 to 0.932) for SUV~max~, 0.733 (95% CI, 0.574 to 0.892) for MTV, and 0.778 (95% CI, 0.629 to 0.928) for TLG. These results indicated that SUV~max~ ~WT~ was the most useful index for predicting patients at high risk of developing any recurrence. The relationship of SUV~max~ ~WT~ with the time of any recurrence was also assessed after adjusting for all available clinicopathological variables. In univariate analysis, increased SUV~max~ ~WT~ (considered as a continuous variable) showed significant association with poorer RFS (p=0.001). The significance of this relationship with RFS was retained in the stepwise multivariate regression analysis (p=0.004) ([Table 4](#t4-crt-2015-172){ref-type="table"}).

The method of Contal and O'Quigley was also used to objectively determine a cut-off point for SUV~max~ ~WT~ \[[@b9-crt-2015-172]\]. According to this method, the best predicted clinical performance was a threshold of 5.36, which provided a sensitivity, specificity, positive predictive value, and negative predictive value of 100%, 71%, 17%, and 100%, respectively. The patients were then divided into two groups (high- vs. low-risk) according to this cut-off point, and the characteristics of patients with SUV~max~ ~WT~ ≥ 5.36 were compared to those of patients with SUV~max~ \< 5.36. PET-based high-risk patients (SUV~max~ ~WT~ ≥ 5.36) had more T1c-T2 (vs. T1a-T1b), high-grade, ER/PR negative, and IDC (vs. non-IDC) tumors than lowrisk patients (SUV~max~ ~WT~ \< 5.36) (all p \< 0.05). Three-year RFS was 85.4% in the PET-based high-risk group compared with 100% in the low-risk group (p \< 0.001) ([Fig. 3A](#f3-crt-2015-172){ref-type="fig"}). The prognosis was much worse when high SUV~max~ (≥ 5.36) was detected in axillary lymph nodes (p \< 0.001) ([Fig. 3B](#f3-crt-2015-172){ref-type="fig"}).

5. Locoregional recurrence in the no-PMRT cohort
------------------------------------------------

In the no-PMRT cohort (n=72), an increased risk of locoregional recurrence was observed for the PET-based high-risk group, compared with the PET-based low-risk group (3-year locoregional recurrence-free survival, 92.9% vs. 100%; p=0.037) ([Fig. 3C](#f3-crt-2015-172){ref-type="fig"}). However, age, T stage, number of positive lymph nodes, histologic grade, ER/PR/HER2 status, ^18^F-FDG--avidity in axillary nodes, and other factors did not show significant association with risk of locoregional recurrence.

Discussion
==========

In this study, we have described the efficacy of PET for identifying patients with T1-T2/N1 breast cancer with a high risk of disease recurrence after mastectomy and standard systemic therapy. We found an association of higher SUV~max~ ~WT~ with both poorer RFS in the entire cohort and a higher risk of locoregional recurrence in the no-PMRT cohort. The SUV~max~ cut-off value that best predicted prognosis was 5.36. Compared with tumors in the PET-defined low-risk group, tumors in the high-risk group were more likely to have the following characteristics: T1c-T2 (vs. T1a-T1b) stage, high grade, ER/PR negativity, and IDC (vs. non-IDC). In conjunction with conventional risk stratification that relies on multiple factors, preoperative ^18^F-FDG/PET information may enable identification of high-risk groups with enhanced accuracy. We hypothesize that once these select groups are identified, they may represent the population of T1-2/N1 breast cancer patients who might benefit from PMRT.

Previous retrospective studies have investigated the usefulness of PET in breast cancer, with findings similar to ours \[[@b10-crt-2015-172]-[@b14-crt-2015-172]\]. Osborne et al. \[[@b10-crt-2015-172]\] reported that ER-- tumors had higher ^18^F-FDG-uptake than ER+ tumors (median SUV~max~, 8.5 vs. 4.0). A study by Mavi et al. \[[@b11-crt-2015-172]\] reported that ER status alone (rather than PR or HER2 status) had an effect on FDG uptake (F=9.126, p \< 0.01). Baba et al. \[[@b12-crt-2015-172]\] reported correlation of high SUV~max~with larger tumor size, higher grade, and triple-negative tumors, as well as poor prognosis (5-year DFS: ≥ 4.16 \[n=32\], 80% vs. \< 4.16 \[n=28\], 100%). Song et al. \[[@b13-crt-2015-172]\] reported that nodal SUV~max~ was the only determinant of DFS among well-known clinical variables in N1-3 patients (n=65), similar to our finding that high SUV~max~ in lymph nodes was associated with worse RFS than high SUV~max~ in the primary tumor. Nakajima et al. \[[@b14-crt-2015-172]\] reported association of MTV and TLG with tumor size, number of positive nodes, nodal ratio, nuclear grade, ER status, and triple negative status. Nakajima et al. \[[@b14-crt-2015-172]\] found that larger MTV was an independent risk factor for locoregional recurrence-free survival and DFS. In comparison with our cohort of patients, the cohort considered by Nakajima et al. \[[@b14-crt-2015-172]\] had different characteristics, including a higher proportion of T2 disease (63% vs. 44%), more biologically aggressive behavior (SUV~max~, MTV, and TLG; median 7.2, 31.7, and 73.4 vs. mean 4.8, 7.1, 20.2), and lesser use of chemotherapy (62.4% vs. 86%). These differences may have increased the importance of MTV in the study by Nakajima et al. \[[@b14-crt-2015-172]\] as compared with our own. However, both studies found that the AUC of SUV~max~ was high (\> 0.80), and the consistency of these findings should be highlighted.

Compared with other studies, our study had the following strengths: (1) the cohort consisted of a homogenous group of patients with pathologic T1-T2/N1 disease, who were treated with mastectomy and current standard adjuvant therapy. In addition, (2) we did not limit the investigation to metabolic (SUV~max~) values, but also assessed volumetric (MTV) values and the combination of both indices (in the form of TLG). The relationships between these indices, RFS, and locoregional recurrence were then evaluated. Finally, (3) the analyses focused on an issue that is currently relevant in clinical practice.

From a cost-effectiveness perspective, it is not clear whether PET should be offered to all patients with T1-T2/N1 disease, in order to identify those at high risk of recurrence, and accordingly indicate PMRT. If our results are confirmed in other series, cost-effectiveness will present another clinical issue. Currently, National Comprehensive Cancer Network (NCCN) experts recommend against the routine use of PET in early breast cancer because of high false-negative rates in small or low grade breast tumors, low sensitivity for detection of nodal metastasis, low prior probability of distant metastasis, and (mainly) cost-ineffectiveness \[[@b15-crt-2015-172]\]. However, recent studies (including studies with prospective designs) have raised the possibility that PET may have a role in stage II breast cancer \[[@b15-crt-2015-172]-[@b19-crt-2015-172]\]. The following studies reported relevant results: Groves et al. \[[@b17-crt-2015-172]\] found that PET impacted cancer management in 16% of patients with stage II disease, Groheux et al. \[[@b15-crt-2015-172]\] reported that PET modified staging in 5.5% of patients with stage IA disease and 13% of patients with stage IB disease, and the Ontario Clinical Oncology Group Study reported that PET could influence surgical care by avoiding unnecessary SLN biopsies \[[@b16-crt-2015-172]\].

Our study has several limitations, including those that are inherent to retrospective analyses. Because of the small number of events (recurrences), it was not possible to perform a more complete statistical analysis. Longer follow-up is needed to clarify the relationship between ^18^F-FDG uptake and dormancy/late recurrence. Although the 5-year OS did not differ significantly according to the use of PET in our cohort (n=712; 5-year OS rate, 93.1% with PET vs. 91% without PET; p=0.412), it is possible that selection bias in our study sample resulted in a better prognosis in the PET group, affecting the results in terms of the cut-off value.

Conclusion
==========

In conclusion, we found that a high SUV~max~ (≥ 5.36) was associated with an increased risk of locoregional recurrence, as well as any recurrence. Patients with high SUV~max~ in lymph node involvement appeared to have a much worse prognosis than those with high SUV~max~ in primary tumors. However, these findings are purely hypothesis generating; confirmatory studies with larger cohorts and longer follow-up periods are necessary before PET-defined risk assessment can be routinely adopted for early breast cancer. Efforts to define the optimal cut-off values of PET parameters are also necessary.
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###### 

Patient, tumor, and treatment characteristics

  Characteristic                                     No. (%) (n=109)
  -------------------------------------------------- -----------------
  **Age (yr)**                                       
   \< 45                                             29 (27)
   ≥ 45                                              80 (73)
  **Histology**                                      
   IDC                                               100 (92)
   Non-IDC                                           9 (8)
  **T stage**                                        
   T1                                                61 (56)
   T1a                                               2 (2)
   T1b                                               15 (14)
   T1c                                               44 (40)
   T2                                                48 (44)
  **LVI**                                            
   Negative                                          102 (94)
   Positive                                          7 (6)
  **No. of positive lymph nodes**                    
   1                                                 69 (63)
   2                                                 29 (27)
   3                                                 11 (10)
  **Percentage of positive lymph nodes**             
   \< 25                                             103 (94)
   ≥ 25                                              6 (6)
  **ECE**                                            
   Negative                                          100 (92)
   Positive                                          9 (8)
  **Histological grade**                             
   1                                                 21 (20)
   2                                                 60 (57)
   3                                                 25 (24)
  **Estrogen receptor status**                       
   Negative                                          25 (23)
   Positive                                          84 (77)
  **Progesterone receptor status**                   
   Negative                                          48 (44)
   Positive                                          61 (56)
  **HER2 overexpression**                            
   Negative                                          73 (69)
   Positive                                          33 (31)
  **Systemic chemotherapy and/or hormone therapy**   105 (96)
   Chemotherapy                                      94 (86)
    AC±T                                             75 (69)
    CMF                                              14 (13)
    Unspecified                                      5 (5)
   Hormone therapy                                   58 (53)
  **Post-mastectomy radiotherapy**                   
   No                                                72 (66)
   Yes                                               37 (34)

IDC, invasive ductal carcinoma; LVI, lymphovascular invasion; ECE, extracapsular extension; AC, adriamycin cyclophosphamide; T, paclitaxel docetaxel; CMF, cyclophosphamide methotrexate 5-fluorouracil.

###### 

Comparisons of PET indices in whole body tumors according to clinicopathologic parameters (n=109)

  Variable                           SUV~max~    p-value    MTV (mL)     p-value   TLG           p-value
  ---------------------------------- ----------- ---------- ------------ --------- ------------- ----------
  **Age (yr)**                                                                                   
   \< 45                             3.99±2.44   0.099      5.15±3.81    0.042     13.84±13.92   0.038
   ≥ 45                              5.09±3.24              7.77±6.46              22.54±28.90   
  **Histology**                                                                                  
   IDC                               5.04±3.07   \< 0.001   7.22±5.75    0.409     21.19±26.52   0.196
   Non-IDC                           2.01±1.08              5.49±8.32              9.47±16.79    
  **T stage**                                                                                    
   T1                                4.12±2.29   0.014      5.40±5.14    0.001     12.17±13.29   \< 0.001
   T2                                5.65±3.70              9.19±6.33              30.46±33.71   
  **LVI**                                                                                        
   Negative                          4.75±3.10   0.570      7.01±6.00    0.671     19.90±26.39   0.551
   Positive                          5.42±2.84              8.04±5.92              24.97±20.37   
  **No. of positive LNs**                                                                        
   1                                 4.43±2.59   0.101      6.22±5.23    0.051     15.84±17.40   0.020
   2, 3                              5.43±3.71              8.54±6.90              27.79±35.37   
  **Positive LNs (%)**                                                                           
   \< 25                             4.82±3.10   0.695      7.17±5.98    0.507     20.34±26.25   0.852
   ≥ 25                              4.31±2.89              5.49±6.10              18.28±23.14   
  **ECE**                                                                                        
   Negative                          4.81±3.08   0.869      6.97±5.61    0.546     19.20±21.59   0.532
   Positive                          4.63±3.25              8.23±9.52              31.57±56.55   
  **Histological grade**                                                                         
   1, 2                              3.97±2.59   \< 0.001   6.04±5.02    0.004     14.05±16.20   0.002
   3                                 7.73±2.85              10.93±7.40             42.04±38.88   
  **Estrogen receptor status**                                                                   
   Negative                          6.66±4.03   0.008      9.50±6.19    0.020     33.72±31.19   0.014
   Positive                          4.24±2.50              6.35±5.75              16.21±22.96   
  **Progesterone receptor status**                                                               
   Negative                          5.52±3.53   0.028      9.22±7.00    0.001     29.37±32.93   0.002
   Positive                          4.22±2.55              5.39±4.38              13.03±15.74   
  **HER2 overexpression**                                                                        
   Negative                          4.73±2.64   0.818      6.77±5.38    0.538     17.44±18.66   0.237
   Positive                          4.90±3.98              7.63±7.10              25.64±37.16   

PET, positron emission tomography; SUV~max~, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; IDC, invasive ductal carcinoma; LVI, lymphovascular invasion; LN, lymph node; ECE, extracapsular extension.

###### 

Comparisons of PET indices in breast, lymph node, and WT according to T classification (n=109)

  T stage   Breast       Lymph node   WT SUV~max~                
  --------- ------------ ------------ -------------- ----------- -----------
  T1a       0/2 (0)      NA           2/2 (100)      NA          NA
  T1b       1/15 (6.7)   1.84±0.39    13/15 (86.7)   3.00±2.80   3.55±2.03
  T1c       0/44 (0)     4.80±1.97    35/44 (79.5)   3.64±2.15   5.59±2.00
  T2        2/46 (4.2)   8.45±4.49    37/48 (77.1)   5.87±4.06   8.94±4.38

Values are presented as number (%) or mean±standard deviation. PET, positron emission tomography; WT, whole body tumors; SUV~max~, maximum standardized uptake value; NA, not applicable.

###### 

Stepwise univariate and multivariate analyses using Cox's regression method for disease-free survival in 109 patients

  Variable                                                  Univariate analysis   Multivariate analysis^[a)](#tfn5-crt-2015-172){ref-type="table-fn"}^                              
  --------------------------------------------------------- --------------------- ---------------------------------------------------------------------- ------- ------ ----------- -------
  Age (≥ 45 yr vs. \< 45 yr)                                0.63                  0.12-3.48                                                              0.597   0.14   0.01-2.24   0.165
  T stage (T1 vs. T2)                                       0.46                  0.08-2.55                                                              0.373   NI     \-          
  No. of positive LNs (1 vs. 2, 3)                          0.77                  0.14-4.22                                                              0.761   0.19   0.01-3.74   0.276
  Histological grade (1, 2 vs. 3)                           0.63                  0.12-3.44                                                              0.593   0.02   0.00-0.73   0.032
  Estrogen receptor status (positive vs. negative)          0.16                  0.03-0.86                                                              0.033   0.04   0.00-0.60   0.02
  Progesterone receptor status (positive vs. negative)      0.76                  0.15-3.76                                                              0.734   NI     \-          \-
  HER2 overexpression (positive vs. negative)               1.19                  0.22-6.51                                                              0.844   NI     \-          \-
  Post-mastectomy radiotherapy (yes vs. no)                 0.39                  0.05-3.41                                                              0.396   0.06   0.00-2.58   0.141
  ^18^F-FDG-avidity in axillary nodes (avid vs. non-avid)   4.30                  0.87-21.29                                                             0.074   NI     \-          \-
  SUV~max~ (as continuous)                                  1.43                  1.15-1.78                                                              0.001   1.77   1.19-2.62   0.004

HR, hazard ratio; CI, confidence interval; LN, lymph node; ^18^F-FDG, ^18^F-fluorodeoxyglucose; SUV~max~, maximum standardized uptake value.

Variables were entered into the multivariate regression model in a stepwise method if p \< 0.20 and were removed at any point if p-value was \> 0.20.

[^1]: Jee Suk Chang and Jeongshim Lee contributed equally to this work.
